The U.S. NIAID (National Institute of Allergy and Infectious Diseases) has claimed that AstraZeneca provided incomplete and outdated efficacy data from latest COVID-19 trial.

AstraZeneca said a day earlier that its Covid-19 vaccines developed with Oxford university was 79% effective in preventing symptomatic illness in large trial in the US, Peru and Chile.

However, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) claimed that AstraZeneca may have provided incomplete view of efficiency data on its vaccine from US trial.

“The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the U.S. agency said, referring to the independent Data Safety Monitoring Board (DSMB).

“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”

Earlier, the European Union called for an Emergency Vaccine Summit after more than a dozen European nations decided to stop using the AstraZeneca COVID-19 vaccine due to serious blood clot incidents reported in many countries.

However, as reported by GreatGameIndia, the Chief Norwegian Investigator and Physician Pal Andre Holme who examined the three hospitalized health workers confirmed that it was indeed the AstraZeneca COVID-19 vaccine which caused the rare blood clots due to unexpected immune reaction.